No Utility Of Routine Laboratory Testing During Surveillance In Detecting Relapse In Patients With Classic Hodgkin Lymphoma In First Remission

Background: Classic Hodgkin lymphoma (CHL) is currently highly curable. Surveillance guidelines have been extrapolated largely from an era where sophisticated staging techniques were lacking, radiotherapy alone was the mainstay of therapy, and cure rates were lower. While the lack of a role for surveillance imaging for patients (pts) in complete remission (CR) at end of therapy (EOT) is well established, there is paucity of data regarding role of laboratory testing. Current NCCN guidelines recommend complete blood counts (CBC), chemistry panels, and erythrocyte sedimentation rate (ESR) “as clinically indicated,” while ESMO recommends testing be performed at each clinic visit. To assess the utility of surveillance laboratory testing in detecting relapse, we conducted a retrospective analysis.